Department of Thoracic Surgery, The Huadong Hospital, Shanghai Fudan University, Shanghai, China.
PLoS One. 2013 Aug 5;8(8):e69553. doi: 10.1371/journal.pone.0069553. Print 2013.
X-ray repair cross-complementing protein 3 (XRCC3) is an essential gene involved in the double-strand break repair pathway. Published evidence has shown controversial results about the relationship between XRCC3 Thr241Met polymorphism and clinical outcomes of non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy.
A systematic review and meta-analysis was performed to evaluate the predictive value of XRCC3 Thr241Met polymorphism on clinical outcomes of advanced NSCLC receiving platinum-based chemotherapy. Response to chemotherapy, overall survival (OS) and progression-free survival (PFS) were analyzed.
A number of 11 eligible studies were identified according to the inclusion criteria. Carriers of the variant XRCC3 241Met allele were significantly associated with good response to platinum-based chemotherapy (ThrMet/MetMet vs. ThrThr: OR = 1.509, 95% CI: 1.099-2.072, Pheterogeneity = 0.618). The XRCC3 Thr241Met polymorphism was not associated with OS (MetMet vs. ThrThr, HR = 0.939, 95% CI:0.651-1.356, Pheterogeneity = 0.112) or PFS (MetMet vs. ThrThr, HR = 0.960, 95% CI: 0.539-1.710, Pheterogeneity = 0.198). Additionally, no evidence of publication bias was observed.
This systematic review and meta-analysis shows that carriers of the XRCC3 241Met allele are associated with good response to platinum-based chemotherapy in advanced NSCLC, while the XRCC3 Thr241Met polymorphism is not associated with OS or PFS.
X 射线修复交叉互补蛋白 3（XRCC3）是参与双链断裂修复途径的必需基因。已发表的证据表明，XRCC3 Thr241Met 多态性与接受铂类化疗的非小细胞肺癌（NSCLC）患者的临床结局之间的关系存在争议。
系统评价和荟萃分析评估了 XRCC3 Thr241Met 多态性对接受铂类化疗的晚期 NSCLC 患者临床结局的预测价值。分析了化疗反应、总生存期（OS）和无进展生存期（PFS）。
根据纳入标准，确定了 11 项符合条件的研究。携带变异 XRCC3 241Met 等位基因的患者对铂类化疗的反应明显更好（ThrMet/MetMet 与 ThrThr：OR = 1.509，95%CI：1.099-2.072，P 异质性 = 0.618）。XRCC3 Thr241Met 多态性与 OS（MetMet 与 ThrThr，HR = 0.939，95%CI：0.651-1.356，P 异质性 = 0.112）或 PFS（MetMet 与 ThrThr，HR = 0.960，95%CI：0.539-1.710，P 异质性 = 0.198）无关。此外，未观察到发表偏倚的证据。
本系统评价和荟萃分析表明，携带 XRCC3 241Met 等位基因的患者对晚期 NSCLC 铂类化疗反应良好，而 XRCC3 Thr241Met 多态性与 OS 或 PFS 无关。
